Ignite Creation Date:
2024-05-05 @ 11:19 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004908
Status:
COMPLETED
Last Update Posted:
2011-08-26
First Post:
2000-03-07
Brief Title:
Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkins Disease or Non-Hodgkins Lymphoma
Sponsor:
Northwestern University
Organization:
Northwestern University
Study Overview
Official Title:
Autologous Blood Stem Cell Transplantation in Patients With Hodgkins Disease and Non-Hodgkins Lymphoma With High-Dose Cyclophosphamide Total Body Irradiation and Involved-Field Radiation Therapy
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Radiation therapy uses high-energy x-rays to damage cancer cells Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more cancer cells
PURPOSE Phase II trial to study the effectiveness of radiation therapy and cyclophosphamide plus peripheral stem cell transplantation in treating patients who have recurrent or refractory Hodgkins disease or non-Hodgkins lymphoma
PURPOSE Phase II trial to study the effectiveness of radiation therapy and cyclophosphamide plus peripheral stem cell transplantation in treating patients who have recurrent or refractory Hodgkins disease or non-Hodgkins lymphoma
Detailed Description:
OBJECTIVES I Determine the toxicity of autologous peripheral blood stem cell transplantation following involved field radiotherapy high dose cyclophosphamide and total body irradiation in patients with recurrent or refractory Hodgkins disease or non-Hodgkins lymphoma II Determine the response in patients treated with this regimen
OUTLINE Patients undergo involved field radiotherapy on days -16 to -7 Patients receive cyclophosphamide IV over 2 hours on days -6 and -5 Patients undergo total body irradiation twice daily on days -4 to -1 Autologous peripheral blood stem cells are reinfused on day 0 Patients are followed every month for 1 year
PROJECTED ACCRUAL Not specified
OUTLINE Patients undergo involved field radiotherapy on days -16 to -7 Patients receive cyclophosphamide IV over 2 hours on days -6 and -5 Patients undergo total body irradiation twice daily on days -4 to -1 Autologous peripheral blood stem cells are reinfused on day 0 Patients are followed every month for 1 year
PROJECTED ACCRUAL Not specified
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-G00-1693 | None | None | None |
| NU-87H5T | None | None | None |